Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 419 clinical trials
Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)

Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor. Its primary targets are Hepatocyte growth factor receptor protein (MET), vascular endothelial growth factor receptor 1-3

transitional cell carcinoma
pd-l1
kinase inhibitor
measurable disease
bladder cancer
  • 46 views
  • 26 Jan, 2021
  • 12 locations
Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia

The treatment of CML and the expected survival has been revolutionised since the introduction of tyrosine kinase inhibitors (TKIs) such as nilotinib. Despite their effectiveness, these drugs

lipase
imatinib
nilotinib
anagrelide
leukemia
  • 10 views
  • 07 Nov, 2020
  • 1 location
VASCular Impact of Angiogenic Treatment in Patients With Advanced Colorectal Cancer

(receptor inhibitors with tyrosine kinase activity), induces hypertension of all grades, observed in 25% to 40 % of patients including 8 to 17% of severe grades ( grade 3 NCI-CTCAE). In terms of

  • 0 views
  • 03 Apr, 2021
  • 1 location
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

Ibrutinib, a first-in-class Bruton Tyrosine kinase (BTK) inhibitor, has become an established treatment in relapsed/refractory chronic lymphocytic leukemia (CLL). However, despite a considerable

  • 2 views
  • 07 Jul, 2021
  • 42 locations
Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma

Acral melanoma is a melanoma that affects acral areas of the skin, which is the most prevalent site of melanoma in non-Caucasians.Data in this subgroup is scarce.This study is to evalueate the efficiency and safety of Neoadjuvant SHR-1210 plus apatinib in this particular group,menawhile to determine the predictive value for …

  • 0 views
  • 03 Jun, 2021
  • 1 location
Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer ALTER-L029

Evaluate the efficacy and safety of Anlotinib following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer

  • 0 views
  • 23 Jan, 2021
  • 4 locations
Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Donafenib for advanced 131I-refractory/resistant differentiated thyroid cancer(DTC).

papillary thyroid carcinoma
ebrt
liver metastasis
metastasis
donafenib
  • 11 views
  • 26 Jan, 2021
  • 1 location
Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Currently the investigators have two different classes of second-line treatment options in recurrent non-small Cell Lung Cancer (NSCLC). In chemotherapy, docetaxel and pemetrexed produced similar treatment efficacy outcomes, while pemetrexed had a better tolerability. In recent analysis of pemetrexed clinical studies, a strong treatment-by-histology interaction in overall survival and progression …

cancer chemotherapy
kinase inhibitor
metastasis
growth factor
alimta
  • 9 views
  • 07 Nov, 2020
  • 1 location
Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure

The primary objective is to compare the efficacy of lenvatinib plus Best Supportive Care versus Placebo plus Best Supportive Care in the treatment of patients with advanced GIST, after failure of imatinib and sunitinib.

  • 0 views
  • 26 Jan, 2021
  • 7 locations
Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)

The aim of this study is to demonstrate that the use of Gleevec in initially non-resectable gastrointestinal stromal tumors can lead to allow complete resection in 20% of cases.

metastasis
complete resection
imatinib
gleevec
partial resection
  • 6 views
  • 07 Nov, 2020
  • 1 location